Duration of Apixaban (Eliquis) for Provoked DVT
For a provoked DVT with a major transient risk factor (such as surgery or trauma), discontinue apixaban after 3 months of treatment. 1, 2
Standard Treatment Protocol
Initial 7-Day Loading Phase
- Apixaban 10 mg orally twice daily for the first 7 days without any preceding parenteral anticoagulation 1, 2
- No heparin bridge is required, unlike with dabigatran or edoxaban 1
Continuation Phase (Day 8 through 3 months)
- Apixaban 5 mg orally twice daily after the loading phase 1, 2
- Continue this dose for a minimum of 3 months total treatment duration 1, 2
Duration Decision Algorithm
Provoked DVT with Major Transient Risk Factor
- Stop anticoagulation after 3 months if the provoking factor was truly transient (e.g., surgery, major trauma, prolonged immobilization) 1, 3
- This represents the standard recommendation from both FDA labeling and European guidelines 1, 2
Provoked DVT with Enduring Risk Factors
- If the patient has persistent risk factors (obesity, heart failure, active cancer, chronic immobility) despite a transient trigger, consider extended therapy with apixaban 2.5 mg twice daily after completing 6 months of standard-dose treatment 1, 4
- Recent high-quality evidence from 2025 demonstrates that patients with provoked VTE plus enduring risk factors had an 87% relative risk reduction in recurrent VTE (1.3% vs 10.0%) when treated with low-dose apixaban for 12 additional months, with minimal bleeding risk 4
Cancer-Associated DVT
- Continue indefinitely at full dose (5 mg twice daily) for cancer-associated thrombosis, as cancer represents a persistent rather than transient risk factor 1, 5
- After 6 months, reduced-dose apixaban 2.5 mg twice daily is noninferior for preventing recurrence and causes less bleeding than full-dose in cancer patients 6
Key Clinical Considerations
Common Pitfall: Do not confuse "provoked" with "low risk." A provoked DVT with enduring risk factors (obesity, heart failure, limited mobility) may warrant extended anticoagulation beyond 3 months 4, 3
Bleeding Safety: The 3-month regimen (10 mg BID × 7 days, then 5 mg BID) demonstrated superior safety compared to enoxaparin/warfarin, with major bleeding rates of 0.6% vs 1.8% (P<0.001) 1, 7
Renal Considerations: Apixaban is contraindicated if creatinine clearance <15 mL/min and should be used cautiously if CrCl 15-29 mL/min 1